Zimmer rated a "buy" after spin-off:
This article was originally published in Clinica
Executive Summary
Analyst JP Morgan has given Zimmer a "buy" rating, with a 12-month target of $34. The orthopaedics company, which has just been spun-off from Bristol-Myers Squibb, is trading at just under $30.